Automated breast ultrasound one step closer to FDA approval

Editorial Staff | | Health Imaging | Diagnostic Imaging
U-Systems has received a pre-market approvable (PMA) letter from the FDA for its somo•v Automated Breast Ultrasound (ABUS) system for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breast tissue. 

Using technology to automate the ultrasound imaging process, the U-Systems’ somo•v ABUS system was developed for the high-volume, breast cancer screening environment. The somo•VIEWer Advanced 3D Workstation enables review and archive of patient exams.

Final approval of the company’s PMA application for the system remains subject to satisfactory review and inspection of U-Systems manufacturing facilities, methods and controls. The company said it plans to work with the FDA to complete this final inspection.

 

Editorial Staff

Related Content

First human X-rays in space to take place during upcoming SpaceX mission
Mycoplasma pneumonia: Experts highlight imaging findings linked to the pediatric diagnosis
AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.